Investors Urged to Act Now in Cytokinetics Class Action Lawsuit Before Deadline

Important Information for Cytokinetics Investors

Levi & Korsinsky, LLP has issued a notice to investors of Cytokinetics, Incorporated, regarding their participation in a class action lawsuit stemming from allegations of securities fraud. Shareholders who have experienced losses due to misleading information shared by the company now have an opportunity to take action before the lead plaintiff deadline on November 17, 2025.

What Is the Class Action About?

This class action lawsuit aims to recover losses for investors of Cytokinetics, whose dealings were impacted by alleged fraudulent activities that occurred between December 27, 2023, and May 6, 2025. During this period, the company purportedly made materially false statements about the timeline for the New Drug Application (NDA) submission and the approval process for a key product, aficamten.

According to the complaint filed, Cytokinetics misled investors by suggesting that they anticipated receiving the U.S. Food and Drug Administration (FDA) approval for aficamten in the later half of 2025. This representation was made in light of a specific PDUFA date of September 26, 2025, which indicated a high level of confidence in a positive outcome. However, the defendants failed to disclose significant risks associated with the company's decision not to submit a required Risk Evaluation and Mitigation Strategy (REMS), which could ultimately delay the regulatory process and the potential approval of the NDA.

Key Developments

On May 6, 2025, during an earnings call, it became public knowledge that Cytokinetics had engaged in several pre-NDA meetings with the FDA. These discussions centered around the aspects of safety monitoring and risk mitigation but left out the vital component of a REMS submission. The conscious choice to abstain from including a REMS in the initial NDA submission suggests that the company was aware of potential regulatory hurdles but intentionally misled shareholders about the timeline and safety considerations.

As a result of these misleading statements, many shareholders acquired Cytokinetics common stock at artificially inflated prices. When the true nature of the company's regulatory challenges came to light, significant losses were incurred by these investors.

Next Steps for Affected Investors

Investors who believe they have suffered financial losses due to Cytokinetics' actions during the defined timeframe have until November 17, 2025, to apply to become a lead plaintiff in this suit. It’s crucial to note that participation in this case does not require one to serve as a lead plaintiff to potentially recover any losses.

No Cost to Participate

Levi & Korsinsky assures investors that if they are affected class members, they may be eligible for compensation without any upfront costs or fees involved. Joining the lawsuit does not come with any financial obligations; hence, it is a risk-free opportunity to seek justice.

Why Levi & Korsinsky?

Levi & Korsinsky boasts a significant history of successful litigation on behalf of shareholders, having recovered hundreds of millions of dollars for aggrieved investors over 20 years. With a dedicated team of over 70 professionals, the firm specializes in complex securities cases and has consistently ranked among the top firms in the U.S. for securities litigation.

For more information about participating in this class action or to discuss your case, reach out to the attorneys at Levi & Korsinsky. Investors can contact Joseph E. Levi, Esq. at (212) 363-7500 or via email at [email protected].

Don't miss this critical opportunity to protect your rights as an investor. Join the class action and help hold Cytokinetics accountable for its alleged misrepresentations and omissions.